Clinical trial NCT05245643: Deep Brain Stimulation for Severe Anorexia Nervosa
Official title: STIMulation cérébrale Profonde Chez Des Patients Souffrant d'Anorexie Mentale Résistante et Sévère
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Anorexia Nervosa
Keywords: Disease Resistance
Deep brain stimulation
Neuropsychological Tests
Patient Acceptance of Health Care
Lead sponsor: Centre Hospitalier St Anne
Sponsor class: OTHER
First posted: 2022-02-18
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective multicenter study: interventional cohort for surgical treatment (deep brain stimulation) in severe and resistant Anorexia Nervosa
Primary purpose: TREATMENT

Brief summary: The somatic complications as well as the suicidal risk make Anorexia Nervosa (AN) the psychiatric disease with the highest mortality rate: the standardized mortality ratio is higher than 4 and 1 in 5 patients with AN who dies has committed suicide. Approximately 20% of patients suffering from AN evolves into a chronic form without prolonged remission. These patients are at high risk of serious complications (somatic and psychiatric). The peak incidence of AN lies between 15 and 19 years: patients suffering from severe and resistant AN are therefore mostly young people. At present, there is no treatment for severe and resistant AN. New insights in AN pathophysiology revealed that AN patients develop a kind of "addiction" to thinness which contributes to weight loss despite negative consequences. In parallel, Deep Brain Simulation (DBS) is now widely performed for movements disorders with good results and low morbidity. DBS is also currently under investigations for other indications such as obsessional compulsive disorder or pharmacoresistant epilepsy. Some case series reported promising results of DBS for severe and resistant AN. The aim of this study is to investigate the safety of nucleus accumbens chronic stimulation for patients enduring severe and resistant AN. Secondary objective is to evaluate patient's acceptance of this new treatment.

Detailed description: Main objective:

To selectively target for neuromodulation the key structures known to be involved in the motivational aspect of food intake, i.e. the nucleus accumbens, while evaluating safety and tolerance in the specific setting of AN patients (monitoring of serious adverse events \[SAE\])

Secondary objectives:

1. Evaluation of patient's acceptance,
2. Effect of DBS on weight stabilization (maintenance of patients' BMI above 14kg/m2),
3. Effect of DBS on pupillometry in patients with severe and resistant AN,
4. Effect of DBS on intermediate clinical variables such as loss of cognitive flexibility, overestimation of delayed rewards, and central coherence defect,
5. Effect of DBS on psychiatric comorbidities of patients suffering from severe and resistant AN.

Prospective multicenter study: interventional cohort

Practical conduct:

A. If all the inclusion criteria are met, proposal to participate in the study allowing a time window of 2 weeks of reflection before giving consent, B. Joint neurosurgeon/psychiatrist information consultation with delivery of a consent form, C. Preoperative assessment carried out after a delay of at least 2 weeks (anaesthesia consultation, brain MRI and neurocognitive assessment), D. Admisison in neurosurgery for one week to perform the DBS procedure. Post-operative CT Scan. The stimulation is turned on for all patients upon discharge from the hospital , E. Joint follow-up visit with the referring physician (once a month) and the neurosurgeon (once every 2 months) for 12 months F. Two neurocognitive assessments during follow-up visit : one early and one late postoperative (respectively at 5 and 11 months)

Inclusion period: 24 months Duration of preoperative assessment and reflection phase: 3 months Duration of participation (treatment + follow-up): 12 months Total duration: 40 months

Statistical analyses:

Descriptive results are presented as means ± standard deviations for continuous data and as percentages for categorical data.

The unpaired and paired t-test because of repeated measures in the same subjects, the Fisher's exact test will be use. A p\<0.05 will be considered as statistically significant. A binomial sequence test is performed after each patient inclusion to check that the rate of SAE remains inferior to 25%.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of Anorexia nervosa according to DSM V criteria.
2. Age 18 to 65 years.
3. Chronic, treatment-resistant anorexia nervosa, defined as:

   * Anorexia nervosa evolving for at least 7 years.
   * Inability to maintain a BMI ≥ 17kg/m² for 2 months following hospitalization in a center specialized for the management of patients suffering from eating disorders according to the criteria of the French Federation of Anorexia and Bulimia nervosa and the Directorate General of Care Provision (Direction Générale de l'Offre de Soins - DGOS, in French). Failure of at least 2 hospitalizations in a specialized center during the history of the disease.
   * Inability to maintain a BMI ≥ 17kg/m² for more than 3 consecutive months during an outpatient treatment conducted by a team specialized for the care of patients suffering from eating disorders according to the criteria of the French Federation of Anorexia and Bulimia and the Directorate General of Care Provision (Direction Générale de l'Offre de Soins - DGOS, in French) in the year preceding the inclusion. Failure of at least 2 outpatient treatments conducted by a specialized team during the AN care.
4. Impaired psychological, social and occupational functioning defined by a score ≤ 45 on the Global Assessment of Functioning Scale.
5. Anorexia nervosa is judged to be the primary disorder if there are psychiatric comorbidities such as depression, anxiety disorder, obsessive-compulsive disorder, or personality disorder by at least two independent experts.
6. The patient is able to comply with the operational and administrative requirements of the study and is able to complete the protocol forms.
7. Patient provides written informed consent.
8. Patient is drug-free or on a medication that has been stable for at least 6 weeks at the time of study entry.
9. If female subject and of childbearing age: use of an effective method of contraception.
10. Membership in a health insurance plan or beneficiary.

Exclusion Criteria:

1. Presence of an Axis I disorder that is primary to anorexia nervosa.
2. Presence of a personality disorder that could compromise compliance with post-surgical follow-up assessed by 2 independent experts
3. Presence of severe neurological pathology or significant MRI abnormalities (excluding anorexia-related atrophy).
4. Cognitive and intellectual ability to understand the risks and constraints of the technique or to give informed consent.
5. Albumin levels \<30g/L.
6. Presence of medical contraindications to undergo implantation of a DBS system or to realize an MRI (pacemaker).
7. Pregnant or breastfeeding woman.
8. Previous DBS.
9. Trusted person and/or family object to patient's participation.
10. Contraindication to general anesthesia.

Primary outcomes:
measure: Rate of serious adverse event
timeFrame: Through study completion (2 years)
Secondary outcomes:
measure: Measure of protocol acceptability
timeFrame: At the end of the inclusions (2 years after study start)
measure: BMI Monitoring
timeFrame: Through study completion (each month), during 2 years
measure: Pupillometry variation
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of Eating Disorder Inventory-2
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of Delayed Discounting Task
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of The Brixton Spatial Anticipation Test
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Trail Making Test
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the slips-of-action task
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Wisconsin Card Sorting Test
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Montreal Cognitive Assessment
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Dubois' five words testing
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Rey-Osterrieth Complex Figure Test (ROCFT)
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Hospital Anxiety and Depression scale
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Scale for Suicide Ideation
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Short Form (36) Health Survey
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Global Assessment of Functioning
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: Scores of the Zarit Burden Interview
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
measure: The Taylor Complex Figure Test (TCFT)
timeFrame: Through study completion: during the preoperative (2 weeks before the surgery), early postoperative (1 month after the surgery), late postoperative (4 months after the surgery) and end of study (11 months after the surgery) neurocognitive assessments
Other outcomes:
Locations:
city: Paris
country: France
facility: Viviane AWASSI
Study officials:
References: